Vitreomacular traction and vitreomacular traction with macular hole are conditions associated with visual disturbance and decreased visual acuity. Recent studies have demonstrated that ocriplasmin is effective and safe in specific patient groups with vitreomacular traction, and hence is recommended as a treatment option. We present here a case report of a patient treated with intravitreal ocriplasmin associated with severe loss of vision and delayed resolution of vitreomacular traction. This report highlights that it is important for patients to be made fully aware of the risks of intravitreal ocriplasmin and the prognosis for visual improvement.